NASDAQ, INC.
ADVISORY, Mar. 13, 2015 (GLOBE NEWSWIRE) --
What:
Acorda Therapeutics, Inc. (Nasdaq:ACOR), a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders, will visit the Nasdaq MarketSite in Times Square to mark the 20th anniversary of the founding of the company.
In honor of the occasion, Ron Cohen, Chief Executive Officer will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Monday, March 16, 2015 – 9:15 a.m. to 9:30 a.m. ET
Acorda Therapeutics, Inc. Media Contact:
Jeff Macdonald
(914) 326-5232
jmacdonald@acorda.com
Nasdaq MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page:
http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr Page:
http://nasdaq.tumblr.com/
Webcast:
A webcast of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Acorda Therapeutics, Inc. (Nasdaq:ACOR):
Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.
Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS), as demonstrated by an increase in walking speed. The Company has one of the leading pipelines in the industry of novel neurological therapies. Acorda is currently developing a number of clinical and preclinical stage therapies. This pipeline addresses a range of disorders including post-stroke walking deficits, Parkinson’s disease, epilepsy, heart failure, MS and spinal cord injury.
For more information, please visit the Company’s website at: www.acorda.com.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $9.1 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or www.business.nasdaq.com.
-NDAQA-
